Emerging human papillomavirus vaccines

Expert Opinion on Emerging Drugs

Volumn 17, Issue 4, 2012, Pages 469-492

  Ma, Barbara ^a   Maraj, Bharat ^a   Tran, Nam Phuong ^a   Knoff, Jayne ^a   Chen, Alexander ^a   Alvarez, Ronald D ^b   Hung, Chien Fu ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Clinical trials; Human papillomavirus; Immunotherapy; Vaccines

Indexed keywords

ADXS 11 001; ALPHA INTERFERON; AMOLIMOGENE BEPIPLASMID; CAPSID PROTEIN L1; CHIMERIC PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; IMIQUIMOD; INTERLEUKIN 6; LIPOPEPTIDE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MVA E 2; PD E 7; SGN 00101; TA HPV; TG 4001; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VGX 3100; VIRUS VECTOR; WART VIRUS VACCINE;

ANTIGEN PRESENTING CELL; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DRUG COST; DRUG EFFICACY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; MICROENCAPSULATION; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; REVIEW; UTERINE CERVIX CARCINOMA; VACCINATION; VIRUS REPLICATION;

ANIMALS; ANUS NEOPLASMS; DRUG DESIGN; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UROGENITAL NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84870419307     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.744393     Document Type: Review

References (190)

1. Hoory T, Monie A, Gravitt P, et al. Molecular epidemiology of human papillomavirus. J Formos Med Assoc 2008;107(3):198-217
2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13(6):607-15
3. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;3124(Suppl 3):S3/11-25
4. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;25401(1):70-9
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;6348(6):518-27
6. Cogliano V, Baan R, Straif K, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6(4):204
7. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8
8. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50
9. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131(10):2349-59
10. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010;46(4 Suppl):S20-6
11. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006;110(5):525-41
12. Kines RC, Thompson CD, Lowy DR, et al. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci USA 2009;106(48):20458-63
13. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009;9(6):347-56
14. Lehoux M, D'Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health genomics 2009;12(5-6):268-80
15. Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology 2012;424(2):77-98
16. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
17. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
18. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131(10):2349-59
19. Schiller JT, Castellsague X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl 10):K53-61
20. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287(16):2120-9
21. Bharti AC, Shukla S, Mahata S, et al. Anti-human papillomavirus therapeutics: facts & future. Indian J Med Res 2009;130(3):296-310
22. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999;17(9):2676-80
23. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340(15):1137-43
24. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367(9509):489-98
25. Venturoli S, Ambretti S, Cricca M, et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 2008;80(8):1434-40
26. Coremans G, Snoeck R. Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions. Expert Opin Pharmacother 2009;10(8):1343-52
27. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J 2006;12(3):5
28. Beglin M, Melar-New M, Laimins L. Human papillomaviruses and the interferon response. J interferon Cytokine Res 2009;29(9):629-35
29. Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis 2009;9:156
30. Cirelli R, Tyring SK. Interferons in human papillomavirus infections. Antiviral Res 1994;24(2-3):191-204
31. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21(1):1-14
32. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114(1):135-41
33. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010;102(7):1129-36
34. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51
35. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;Nov13-19364(9447):1757-65
36. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8(12):1663-79
37. Lin K, Doolan K, Hung CF, et al. Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 2010;109(1):4-24
38. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53(Suppl 1):S5-S11
39. Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Phila) 2012;5(1):18-23
40. Harper DM, Williams KB. Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discov Med 2010;10(50):7-17
41. Campo MS, Roden RB. Papillomavirus prophylactic vaccines: established successes, new approaches. J Virol 2010;84(3):1214-20
42. Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus- 16/18 cervical cancer vaccine, Cervarix. Adv Ther 2009;26(11):983-98
43. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/ 18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24(33-34):5937-49
44. Ault KA. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27
45. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861-8
46. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70
47. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14
48. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
49. Goldstone SE, Vuocolo S. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18. Expert Rev Vaccines 2012;11(4):395-406
50. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369(9574):1693-702
51. Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401
52. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43
53. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365(17):1576-85
54. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364(5):401-11
55. Ma B, Roden R, Wu TC. Current status of human papillomavirus vaccines. J Formos Med Assoc 2010;109(7):481-3
56. Bharadwaj M, Hussain S, Nasare V, et al. HPV & HPV vaccination: issues in developing countries. Indian J Med Res 2009;130(3):327-33
57. Garnett GP, Kim JJ, French K, et al. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006;24(Suppl 3):S3/178-86
58. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011;7(12):1374-86
59. Dorans K. Fewer shots proposed to increase uptake of HPV vaccine. Nat Med 2010;16(8):832-3
60. Rowhani-Rahbar A, Carter JJ, Hawes SE, et al. Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines. J Infect Dis 2009;200(9):1452-5
61. Frazer IH. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010;118(1 Suppl):S8-11
62. Brun JL, Dalstein V, Leveque J, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011;204(2):169; e1-8
63. Roteli-Martins C, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012;8(3):390-7
64. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5(10):705-19
65. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7(12):1343-58
66. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):100-10
67. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89-99
68. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008;109(2 Suppl):S15-21
69. Merck. A phase iii clinical trial to study the immunogenicity, tolerability, and manufacturing consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in preadolescents and adolescents (9 to 15 Year Olds) with a comparison to young women (16 to 26 Year Olds). In: ClinicalTrials.gov [Internet] National Library of Medicine (US); Bethesda (MD): 2009
70. Merck. A randomized, double-blinded, tolerability and immunogenicity study of a multivalent human papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine administered concomitantly with GARDASIL to 16- to 26-Year-Old women. Oct 29 edition. In: ClinicalTrials.gov [Internet] National Library of Medicine (US); Bethesda (MD): 2007
71. Merck. A phase IIa randomized, double-blind controlled with gardasil, clinical trial to study thetolerability and immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in healthy 16 to 26 year old women. Aug 22 edition. In: ClinicalTrials.gov [Internet] National Library of Medicine (US); Bethesda (MD): 2007
72. Merck. A randomized, international, double-blinded (With In-House Blinding), controlled with GARDASIL, dose-ranging, tolerability, immunogenicity, and efficacy study of a multivalent human papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine administered to 16- to 26- year-old women. Oct 12 edition. In: ClinicalTrials.gov [Internet] National Library of Medicine (US); Bethesda (MD): 2007
73. Li M, Cripe TP, Estes PA, et al. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol 1997;71(4):2988-95
74. Rose RC, White WI, Li M, et al. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998;72(7):6151-4
75. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007;14(10):1285-95
76. Schadlich L, Senger T, Gerlach B, et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 2009;83(15):7690-705
77. Karanam B, Jagu S, Huh WK, et al. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol 2009;May-Jun87(4):287-99
78. Embers ME, Budgeon LR, Pickel M, et al. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002;76(19):9798-805
79. Gaukroger JM, Chandrachud LM, ÓNeil BW, et al. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996;77(Pt 7):1577-83
80. Roden RB, Yutzy WHt, Fallon R, et al. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 2000;270(2):254-7
81. Pastrana DV, Gambhira R, Buck CB, et al. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005;337(2):365-72
82. Kawana K, Yoshikawa H, Taketani Y, et al. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol 1999;73(7):6188-90 and 16.
83. Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007;81(24):13927-31
84. Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007;81(21):11585-92
85. Yoon SW, Lee TY, Kim SJ, et al. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine 2012;30(22):3286-94
86. Tumban E, Peabody J, Peabody DS, et al. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PloS One 2011;6(8):e23310
87. Caldeira Jdo C, Medford A, Kines RC, et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010;28(27):4384-93
88. Jagu S, Karanam B, Gambhira R, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009;101(11):782-92
89. Jagu S, Kwak K, Garcea RL, et al. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010;28(28):4478-86
90. Tuma RS. Assessing the HPV vaccine: researchers confront complex interplay of factors. J Natl Cancer Inst 2009;101(7):444-5
91. Kondo K, Ochi H, Matsumoto T, et al. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol 2008;80(5):841-6
92. Kanda T, Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccin 2009;Jan-Feb5(1):43-5
93. Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009;83(19):10085-95
94. Lin J, Xu J, Albers AE, et al. New developments in therapeutic HPV vaccines. Curr Obstet Gynecol Rep 2012;1(3):106-15
95. Lin K, Roosinovich E, Ma B, et al. Therapeutic HPV DNA vaccines. Immunol Res 2010;47(1-3):86-112
96. Souders NC, Sewell DA, Pan ZK, et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8 + T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun 2007;7:2
97. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008;26(41):5315-20
98. Adachi K, Kawana K, Yokoyama T, et al. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 2010;28(16):2810-17
99. Quistian-Martinez D, Villatoro-Hernandez J, Loera-Arias MJ, et al. Efficient secretion of a modified E7 protein from human papilloma virus type-16 by Lactococcus lactis. Lett Appl Microbiol 2010;51(4):383-7
100. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009;27(30):3975-83
101. Radulovic S, Brankovic-Magic M, Malisic E, et al. Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C. J BUON 2009;14(Suppl 1):S165-8
102. Advaxis. REALISTIC: A Phase I, Dose Escalation Trial Of Recombinant Listeria Monocytogenes (Lm)-Based Vaccine Encoding Human Papilloma Virus Genotype 16 Target Antigens (ADXS11- 001) In Patients With HPV-16 +ve Oropharyngeal Carcinoma.
103. NCI. A Phase II Evaluation of ADXS11-001 (NSC 752718, BB-IND#13,712) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix.
104. Advaxis. A Randomized, Single Blind, Placebo Controlled Phase 2 Study to Assess the Safety of ADXS11-001 for the Treatment of Cervical Intraepithelial Neoplasia Grade 2/3.
105. Wallecha A, French C, Petit R, et al. Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol 2012;2012:542851
106. Lee DW, Anderson ME, Wu S, et al. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus- positive cancer. Arch Otolaryngol Head Neck Surg 2008;134(12):1316-23
107. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 2007;56(7):997-1007
108. Daemen T, Riezebos-Brilman A, Regts J, et al. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004;9(5):733-42
109. Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004;22(3-4):520-7
110. Velders MP, McElhiney S, Cassetti MC, et al. Eradication of established tumors by vaccination with venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001;61(21):7861-7
111. Hibbitts S. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases. Curr Opin Mol Ther 2010;12(5):598-606
112. Zurkova K, Babiarova K, Hainz P, et al. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. Oncol Rep 2009;21(5):1335-43
113. Hsieh CJ, Kim TW, Hung CF, et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 2004;22(29-30):3993-4001
114. Lamikanra A, Pan ZK, Isaacs SN, et al. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 2001;75(20):9654-64
115. Kaufmann AM, Stern PL, Rankin EM, et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8(12):3676-85
116. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347(9014):1523-7
117. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/ 18 oncoproteins. Cancer Res 2003;63(18):6032-41
118. Baldwin PJ, van der Burg SH, Boswell CM, et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003;9(14):5205-13
119. Adams M, Borysiewicz L, Fiander A, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001;19(17-19):2549-56
120. Cancer EOfRaTo. A phase II trial in patients with early cervical cancer to study the safety and the immunological effects of vaccination with TA-HPV, a live recombinant vaccinia virus expressing the human papilloma virus 16 and 18 E6 and E7 proteins. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US).1999
121. Corona Gutierrez CM, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004;15(5):421-31
122. Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006;13(6):592-7
123. Albarran YCA, de la Garza A, Cruz Quiroz BJ, et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs 2007;21(1):47-59
124. Transgene. Transgene Reports Randomized Phase 2b Data with its Therapeutic HPV Vaccine TG4001 in Women with CIN2/3 Intraepithelial Cervical Neoplasia. 2012. Available from: http://www.transgene.fr/index.php?option=com- press-release&task=download&id=208&l=en [Cited 20 July 2012]
125. Fiander AN, Tristram AJ, Davidson EJ, et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 2006;May-Jun16(3):1075-81
126. University JH. Vaccine therapy with or without imiquimod in treating patients with grade 3 cervical intraepithelial neoplasia. In: ClinicalTrials.gov [Internet] National Library of Medicine (US); Bethesda (MD): 2008
127. Qin Y, Wang XH, Cui HL, et al. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. Gynecol Oncol 2005;96(2):475-83
128. Sharma RK, Elpek KG, Yolcu ES, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009;69(10):4319-26
129. Yan W, Chen WC, Liu Z, et al. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine 2010;52(3):238-44
130. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169(1):350-8
131. Daftarian P, Mansour M, Benoit AC, et al. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 2006;24(24):5235-44
132. Zhang YQ, Tsai YC, Monie A, et al. Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine 2010;28(32):5212-19
133. Wu CY, Yang HY, Monie A, et al. Intraperitoneal administration of poly(I: C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol Immunother 2011;60(8):1085-96
134. Barrios K, Celis E. TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother 2012;61(8):1307-17
135. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998;4(9):2103-9
136. van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999;35(6):946-52
137. Ressing ME, van Driel WJ, Brandt RM, et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000;Mar-Apr23(2):255-66
138. Muderspach L, Wilczynski S, Roman L, et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6(9):3406-16
139. Kenter GG, Welters MJ, Valentijn AR, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14(1):169-77
140. Welters MJ, Kenter GG, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14(1):178-87
141. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361(19):1838-47
142. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010;107(26):11895-9
143. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 2012;61(9):1485-92
144. Cui Z, Huang L. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 2005;54(12):1180-90
145. Stewart TJ, Drane D, Malliaros J, et al. ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines. Vaccine 2004;22(27-28):3738-43
146. Kang TH, Monie A, Wu LS, et al. Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine 2011;29(5):1082-9
147. Preville X, Ladant D, Timmerman B, et al. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005;65(2):641-9
148. Chu NR, Wu HB, Wu T, et al. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 2000;121(2):216-25
149. Liu H, Wu BH, Rowse GJ, et al. Induction of CD4-independent E7- specific CD8+ memory response by heat shock fusion protein. Clin Vaccine Immunol 2007;14(8):1013-23
150. Liao CW, Chen CA, Lee CN, et al. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects. Cancer Res 2005;65(19):9089-98
151. Granadillo M, Vallespi MG, Batte A, et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine 2011;29(5):920-30
152. Huang CY, Chen JJ, Shen KY, et al. Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS ONE 2012;7(7):e40970
153. Derkay CS, Smith RJ, McClay J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 2005;114(9):730-7
154. Goldstone SE, Palefsky JM, Winnett MT, et al. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 2002;45(4):502-7
155. Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007;106(3):558-66
156. Einstein MH, Kadish AS, Burk RD, et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 2007;106(3):453-60
157. Van Doorslaer K, Reimers LL, Studentsov YY, et al. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol 2010;116(2):208-12
158. Newswire P. Nventa Announces Final Data from HspE7 Phase 1 Cervical Dysplasia Trial. PR Newswire United Business Media: PR Newswire Association LLC 2008
159. Center SKCC. A pilot study of pnGVL4a-CRT/E7 (Detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). In: ClinicalTrialsgov [Internet] National Library of Medicine (US); Bethesda (MD): 2009
160. Klencke B, Matijevic M, Urban RG, et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 2002;8(5):1028-37
161. Sheets EE, Urban RG, Crum CP, et al. Immunotherapy of human cervical
162. Garcia F, Petry KU, Muderspach L, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2004;103(2):317-26
163. Alvarez-Salas LM. Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia. Curr Opin Mol Ther 2008;10(6):622-8
164. Matijevic M, Hedley ML, Urban RG, et al. Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. Cell Immunol 2011;270(1):62-9
165. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009;17(4):585-92
166. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy Against HPV16/ 18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses. Sci Transl Med 2012;4(155):155ra38
167. Pharmaceuticals I. Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/ E7 DNA Vaccine) Delivered IM Followed by Electroporation With Cellectra-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.
168. Trimble CL, Peng S, Kos F, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16 + cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009;15(1):361-7
169. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009;15(22):6758-62
170. Bilu D, Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149(Suppl 66):5-8
171. Chuang CM, Monie A, Hung CF, et al. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 2010;17:32
172. Santin AD, Bellone S, Palmieri M, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008;82(4):1968-79
173. Tseng CW, Trimble C, Zeng Q, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother 2009;58(5):737-48
174. Kang TH, Lee JH, Song CK, et al. Epigallocatechin-3-gallate enhances CD8 + T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007;67(2):802-11
175. Tseng CW, Hung CF, Alvarez RD, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008;14(10):3185-92
176. Tseng CW, Monie A, Wu CY, et al. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) 2008;86(8):899-908
177. Zeng Q, Peng S, Monie A, et al. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 2011;22(7):809-19
178. Peng S, Monie A, Pang X, et al. Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci 2011;18:21
179. Chuang CM, Monie A, Wu A, et al. Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects. J Biomed Sci 2009;16:49
180. Transgene. Transgene and Roche Modify the Clinical Development Programme for their HPV-targeted Immunotherapy TG4001/R3484. 2008. [cited 2012 July 20]; Available from: http://www.transgene.fr/index.php?option=com-press- release&task=download&id=22&l=en
181. Frazer IH, Quinn M, Nicklin JL, et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004 Nov 25;23(2):172-81.
182. Anderson JS, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J Acquir Immune Defic Syndr 2009 Nov 1;52(3):371-81.
183. Hallez S, Simon P, Maudoux F, et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer immunology, immunotherapy : CII 2004 Jul;53(7):642-50.
184. Palefsky JM, Berry JM, Jay N, et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 2006;20(8):1151-5
185. Center, SKCC. A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2005
186. Pharmaceuticals, I. Phase I Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Post Surgical or Ablative Treatment of Grade 2 or 3 Cervical Intraepithelial Neoplasia (CIN). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).
187. Pharmaceuticals, I. Phase I, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of a Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation (EP) in Adult Females Previously Immunized With VGX-3100. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)
188. Hospital, NTU A Pilot Study for the Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs) Pulsed With Human Papillomavirus Type 16 E7 Antigen. In: ClinicalTrials. gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2005
189. Smyth LJ, Van Poelgeest MI, Davidson EJ et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004;10:2954-2961.
190. Davidson EJ, Faulkner RL, Sehr, P et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunization in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004;22:2722-2729